Molika Ashford

Investigators embraced recently developed computational tools, with guidance from experts, to assess whether protein structure data can help predict the effects of gene variants.

The company has been offering the test on a limited basis but now plans to market it more broadly after a large validation study showed high sensitivity and specificity.

The firm believes its platform, which uses a swallowable capsule sample collection device, can improve the identification and care of patients with esophageal pre-cancer.

The company welcomed favorable results last week from a study comparing its test to a narrower ddPCR-based approach in patients from an ongoing interventional trial.

Leaders from diagnostics firms and academia discussed the challenges of assessing these tests and the need for a consensus on how to bring them to the clinic.

A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.

Researchers confirmed prior data showing 100 percent accuracy for the test, but in a clinical-use population where they also observed growing adoption by physicians.

The group recently published a case-control study showing high sensitivity and specificity, with little drop in early-stage disease, compared to late-stage cancer.

Company officials lauded its core tests and shared news about launches planned for the upcoming year, including its minimal residual disease assay.

The company attributed the growth to both a boost in test volume and improved reimbursement rates from both Medicare and private payors.